Chaperone-mediated proteostasis is a cornerstone of cellular protein quality control. The heat shock protein (Hsp) family — including Hsp70, Hsp40, Hsp90, and small Hsps — facilitates protein folding, prevents aggregation, and targets misfolded proteins for degradation via the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-dysfunction-neurodegeneration) or [autophagy-lysosomal pathway](/mechanisms/autophagy-lysosomal-dysfunction). This comparison examines how chaperone systems are altered across major neurodegenerative diseases.
Chaperone-mediated proteostasis is a cornerstone of cellular protein quality control. The heat shock protein (Hsp) family — including Hsp70, Hsp40, Hsp90, and small Hsps — facilitates protein folding, prevents aggregation, and targets misfolded proteins for degradation via the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-dysfunction-neurodegeneration) or [autophagy-lysosomal pathway](/mechanisms/autophagy-lysosomal-dysfunction). This comparison examines how chaperone systems are altered across major neurodegenerative diseases.
| Chaperone System | Alzheimer's Disease | Parkinson's Disease | ALS/FTD | Huntington's Disease |
|-----------------|---------------------|-------------------|---------|---------------------|
| Hsp70 (HSPA family) | ↓ Hsp70 in AD brain; HSPA1L variants associated with risk | ↓ Hsp70 in SNc; PINK1/PARKIN regulate Hsp70 activity | Reduced Hsp70 in ALS motor cortex; C9orf72 hexanucleotide expansion affects chaperone network | Hsp70 induction protective in HD models; mutant HTT interferes with Hsp70 function |
| Hsp40 (DNAJ family) | DNAJA1, DNAJB1 reduced in AD; co-chaperone dysfunction | DNAJB6, DNAJB8 mutations cause PD; critical for α-synuclein folding | DNAJC proteins mutated in ALS (DNAJC7); TDP-43 affects J-domain function | DNAJC13 (RECA1) linked to HD; mutant HTT sequesters DNAJ proteins |
| Hsp90 (HSP90AA1) | Hsp90 inhibitors in AD clinical trials; targets tau, Aβ | Hsp90 inhibitors reduce α-synuclein toxicity | Hsp90 inhibition reduces SOD1, TDP-43 aggregation | Hsp90 inhibition reduces mutant HTT aggregation |
| Small Hsps (HspB family) | HspB2/B4 decreased in AD; αB-crystallin (HspB5) protects against tau | HspB5 (αB-crystallin) inhibits α-synuclein aggregation | HspB8 mutations cause ALS; HspB1 (Hsp27) protective | HspB8 reduces mutant HTT aggregation |
| Co-chaperones (TPR, J-domain) | BAG family, HOP, CHIP (STUB1) regulate Hsp70/90 | BAG proteins dysregulated in PD; PINK1 phosphorylates Hsp90 | STUB1 (CHIP) mutations cause ALS/FTD | BAG3 critical for autophagy in HD |
In AD, the amyloid-β (Aβ) and tau pathologies are closely linked to chaperone system failure. The [amyloid cascade hypothesis](/mechanisms/amyloid-cascade) is modulated by chaperone activity:
Chaperone systems are central to [α-synuclein](/proteins/alpha-synuclein) pathology in PD:
The [protein aggregation](/mechanisms/protein-aggregation-disease-comparison) seen in ALS and FTD involves TDP-43, SOD1, FUS, and C9orf72:
The [mutant huntingtin](/genes/huntingtin) (mHTT) protein actively disrupts chaperone networks:
All five diseases share chaperone system impairment:
| Target | Approach | Disease | Status |
|--------|----------|---------|--------|
| Hsp70 inducers | Arimoclomol, BGP-15 | ALS, PD | Clinical trials (NCT00706147, NCT02412535) |
| Hsp90 inhibitors | Geldanamycin derivatives | AD, PD, HD | Preclinical/Phase I |
| Hsp70/90 co-chaperones | BAG antagonists, J-domain proteins | All | Preclinical |
| Small Hsp modulators | αB-crystallin delivery | AD, PD | Preclinical |
| HSF1 activators | Geranylgeranylacetone | AD | Clinical trial (NCT03061929) |
The Hsp70 family constitutes the primary chaperone system for protein folding in neurons. The canonical cycle involves Hsp70 binding to nascent or misfolded polypeptides through its substrate-binding domain (SBD), with ATP hydrolysis regulated by Hsp40 (DNAJ) co-chaperones. The ADP-bound state has high affinity for substrate; nucleotide exchange factors (NEFs) like BAG family members catalyze ADP release, allowing ATP rebinding and substrate release[@brehme_hsp70_aging].
In neurodegeneration, several interconnected mechanisms compromise Hsp70 function:
DNAJ proteins (Hsp40) are the largest chaperone co-chaperone family, with over 40 members in humans. They function primarily by:
Hsp90 is unique among chaperones in its specificity for a defined set of "client" proteins, many of which are signaling kinases and transcription factors. In neurodegeneration, Hsp90 has a paradoxical role — it stabilizes both beneficial (neurotrophic signaling proteins) and pathogenic (disease-causing mutant proteins) clients[@ravid_hsp90_brain].
In AD: Hsp90 forms stable complexes with both tau and Aβ. Hsp90 inhibitors reduce amyloid production by destabilizing BACE1 (β-secretase), but this approach has faced clinical challenges due to toxicity and insufficient CNS penetration.
In ALS: Hsp90 is critical for SOD1 stability — mutant SOD1 misfolds rapidly in the absence of Hsp90 protection. Hsp90 inhibition accelerates aggregation, paradoxically making it a challenging therapeutic target[@toubiana_hsp90_sod1].
The small Hsp family (12-42 kDa) functions differently from Hsp70/Hsp90 — they form large oligomers that bind early-stage aggregation intermediates, preventing fibril formation rather than promoting refolding.
HspB5 (αB-crystallin): Expressed at high levels in astrocytes and oligodendrocytes. In AD, αB-crystallin binds to phosphorylated tau and prevents its aggregation into neurofibrillary tangles. The decreased expression observed in AD brain may contribute to tangle formation[@johannesen_hspb5_tau].
HspB8 (Hsp22): Critical for macroautophagy of aggregate-prone proteins through its interaction with BAG3. Mutations in HSPB8 cause autosomal dominant ALS, impairing the clearance of TDP-43 aggregates. In HD, HspB8 overexpression reduces mHTT aggregation and is neuroprotective.
HSF1 is the master transcription factor for the heat shock response. Under normal conditions, HSF1 is kept inactive by association with Hsp90 and Hsp70 in a multi-chaperone complex. Proteostatic stress causes Hsp90/Hsp70 to release HSF1, which trimerizes, enters the nucleus, and activates transcription of Hsp genes and other protective genes[@morimoto_hsf1_aging].
In aging and neurodegeneration, HSF1 function declines through several mechanisms:
Geranylgeranylacetone (GGA) is an HSF1 activator that has been tested in clinical trials for AD (NCT03061929)[@masser_geranylgeranylacetone]. It works by transiently depleting the Hsp90/Hsp70 pool, creating a temporary proteostatic stress that activates HSF1 without causing cell damage.
Arimoclomol is another HSF1 activator that extends survival in SOD1 mouse models and has progressed to clinical trials for ALS. It acts as a co-inducer of the heat shock response, amplifying the signal when HSF1 is partially activated.
Chaperone-mediated autophagy (CMA) is a selective degradation pathway where Hsc70 (HSPA8) recognizes KFERQ-like motifs in substrate proteins and delivers them to the lysosomal membrane for internalization through LAMP-2A receptors[@rodriguez_chaperone_autophagy].
Steps in CMA:
In AD: CMA activity declines with age and in AD brain. Key targets of CMA include tau and Aβ, and reduced CMA contributes to their accumulation. LAMP-2A is decreased in AD brain, and restoring CMA activity reduces pathology in models.
In PD: α-Synuclein is a major CMA substrate — it contains a KFERQ-like motif and is degraded via CMA under normal conditions. Post-translational modifications (phosphorylation, oxidation) block CMA recognition, causing α-synuclein to accumulate and aggregate. Mutations that cause familial PD (A53T, A30P) are particularly resistant to CMA.
In HD: mHTT is partially degraded by CMA, but the large polyglutamine tract makes it a difficult substrate. CMA impairment contributes to mHTT accumulation.
Macrophage CMA: Emerging evidence suggests that microglia utilize CMA for inflammatory protein turnover, and impaired microglial CMA contributes to chronic neuroinflammation.
BAG proteins are nucleotide exchange factors for Hsp70, catalyzing the transition from ADP to ATP for substrate release:
| BAG Protein | Key Functions | Role in Neurodegeneration |
|-------------|--------------|--------------------------|
| BAG1 | Targets Hsp70 clients to proteasome | Decreased in AD |
| BAG2 | Inhibits CHIP-mediated degradation | Dysregulated in PD |
| BAG3 | Bridges Hsp70 to autophagy (BAG3-Hsc70-HspB8) | Critical in ALS/HD; mutations cause disease |
| BAG5 | Localizes to mitochondria; regulates PINK1 | PD-relevant |
BAG3 is particularly important — it forms a complex with Hsc70 and HspB8 that drives macroautophagy of large aggregates (e.g., mHTT, SOD1). BAG3 variants are associated with ALS susceptibility[@chen_bag3_als]. BAG3 knockdown causes accumulation of protein aggregates, while BAG3 overexpression enhances aggregate clearance.
CHIP (C-terminal Hsp70 Interacting Protein, encoded by STUB1) is a multi-functional co-chaperone with both co-chaperone activity (via TPR domain binding to Hsp70/Hsp90) and E3 ubiquitin ligase activity. CHIP ubiquitinates misfolded proteins, directing them to the proteasome.
In AD: CHIP ubiquitinates tau and Aβ, promoting their degradation. STUB1 variants modify AD risk.
In ALS/FTD: Loss-of-function mutations in STUB1 cause a recessive form of ALS/FTD, confirming the critical role of CHIP in neuronal protein quality control.
HOP acts as a bridge between Hsp70 and Hsp90, facilitating the transfer of client proteins from Hsp70 (folding) to Hsp90 (stabilization). In neurodegeneration, HOP levels may shift the balance between refolding and degradation pathways.
Chaperones are increasingly recognized as modulators of neuroinflammation[@kakimura_microglial_hsp70]:
The GGGGCC hexanucleotide repeat expansion in C9orf72 — the most common genetic cause of familial ALS and FTD — profoundly impacts the chaperone network[@ross_c9orf72_hsp]:
The net effect is that C9orf72 expansion creates a massive burden on the chaperone system — both through loss-of-function (reduced C9orf72 protein) and gain-of-function (DPR sequestration of chaperones).
Arimoclomol: Co-inducer of Hsp70 transcription; extends survival in SOD1-G93A mice. Tested in ALS Phase 2/3 trial (NCT00706147). Works synergistically with other heat shock activators.
BGP-15: Hydroxyamine derivative that activates Hsp70; showed benefit in PD models (NCT02412535). May also have PARP-inhibitory effects.
Geranylgeranylacetone (GGA): Originally developed for gastric ulcers; induces Hsp70 through HSF1 activation. In AD models, GGA reduces Aβ pathology and improves cognition.
Geldanamycin and derivatives: Natural product that binds Hsp90 ATP-binding pocket, inhibiting its chaperone activity. Causes degradation of Hsp90 client proteins (including disease-relevant proteins like tau, α-syn, HTT). 17-AAG (tanespimycin) and 17-DMAG (alvespimycin) were tested in clinical trials but faced challenges with toxicity and formulation.
PU-H71: Purine-scaffold Hsp90 inhibitor with better CNS penetration. Currently in clinical trials for cancer; being explored for neurodegenerative diseases.
AT13387: Second-generation Hsp90 inhibitor with improved pharmacokinetics.
| Model | Chaperone Relevance |
|-------|---------------------|
| Primary neurons (mouse/rat) | Endogenous chaperone response to proteostatic stress |
| iPSC-derived neurons | Human chaperone biology; patient-specific mutations |
| Glial cell cultures | Microglial and astrocyte chaperone modulation of inflammation |
| Organotypic brain slices | Preserved tissue architecture; chaperone drug testing |
Chaperone system failure is a unifying feature across AD, PD, ALS, FTD, and HD. Each disease exhibits distinct patterns: AD shows decreased small Hsp expression and impaired tau handling; PD involves DNAJB6 mutations and α-synuclein sequestration of Hsp70; ALS features STUB1/CHIP mutations and C9orf72-driven chaperone disruption; HD presents HTT-mediated Hsp70 depletion and BAG3 dysfunction. The therapeutic approach must be tailored — Hsp70 induction for AD/HD, disaggregase enhancement for PD, and CHIP augmentation for ALS — with the goal of restoring proteostasis before irreversible neuronal loss occurs.